<DOC>
	<DOCNO>NCT01748370</DOCNO>
	<brief_summary>Low total testosterone ( TT ) present 30 % men age &gt; 60 year 7 % young men . Male hypogonadism associate metabolic cardiovascular disease well increase mortality . There evidence show relationship TT vitamin D men . We aim evaluate effect vitamin D supplementation TT metabolic parameter hypogonadal men . We study effect 20,000 IU vitamin D weekly 12 wk randomize , double-blind , placebo-controlled trial 100 men TT &lt; 3.0 ng/ml 25-hydroxyvitamin D ( 25 ( OH ) D ) &lt; 30 ng/ml ( patient ) well 100 men TT ≥3.0 ng/ml 25 ( OH ) D &lt; 30 ng/ml ( control ) . Vitamin D supplementation might safe therapeutic approach improve TT level well metabolic parameter hypogonadal men . Further effect vitamin D androgen evaluate eugonadal men .</brief_summary>
	<brief_title>Vitamin D Treatment Hypogonadism Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Hypogonadal men : TT level 3.0 ng/ml ( measure baseline visit confirm study visit 1 ) 25 ( OH ) D level 30 ng/ml ( measure baseline visit ) Male , age ≥ 18 &lt; 70 year Written inform consent enter study Hypercalcemia define serum calcium &gt; 2,7 mmol/L Oral transdermal testosterone supplementation last 2 month enter study IM testosterone supplementation 6 month enter study Regular intake vitamin D supplement study entry Men chronic disease ( diabetes mellitus , thyroid disease , endocrine disturbance need treatment ( except hypogonadism ) , diseases know interfere vitamin D intake sensitive vitamin D intake ( inflammatory disease granuloma : sarcoidoses , tuberculosis , Mb Wegener , vasculitis , inflammatory bowel disease Intake medication influence metabolic endocrine parameter ( insulin sensitizer , insulin , glucocorticoid , … ) last 3 month study entry PSA &gt; 4 ng/ml ( &gt; 3 ng/ml men high risk prostate cancer ) ( see state art ) Palpable prostate nodule induration Hematocrit &gt; 50 % Untreated severe obstructive sleep apnea Severe low urinary tract symptom Uncontrolled poorly control heart failure A history prostate cancer , breast cancer , orchidectomy , chromosomal disorder ( e.g . Klinefelter Syndrome ) Eugonadal men : TT level ≥3.0 ng/ml ( measure baseline visit confirm study visit 1 ) 25 ( OH ) D level 30 ng/ml ( measure baseline visit ) Male , age ≥ 18 &lt; 70 year Written inform consent enter study Hypercalcemia define serum calcium &gt; 2,7 mmol/L Oral transdermal testosterone supplementation last 2 month enter study IM testosterone supplementation 6 month enter study Regular intake vitamin D supplement study entry Men chronic disease ( diabetes mellitus , endocrine disturbance need treatment ( except hypogonadism ) , diseases know interfere vitamin D intake sensitive vitamin D intake ( inflammatory disease granuloma : sarcoidoses , tuberculosis , Mb Wegener , vasculitis , inflammatory bowel disease Intake medication influence metabolic endocrine parameter ( insulin sensitizer , insulin , glucocorticoid , … ) last 3 month study entry PSA &gt; 4 ng/ml ( &gt; 3 ng/ml men high risk prostate cancer ) ( see state art ) Palpable prostate nodule induration Hematocrit &gt; 50 % Untreated severe obstructive sleep apnea Severe low urinary tract symptom Uncontrolled poorly control heart failure A history prostate cancer , breast cancer , orchidectomy , chromosomal disorder ( e.g . Klinefelter )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>vitamin D</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone</keyword>
	<keyword>intervention</keyword>
</DOC>